Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2

Gupta, Parth Sarthi Sen; Biswal, Satyaranjan; Singha, Dipankar; Rana, Malay Kumar

doi:10.1080/07391102.2020.1784795

Cited by 27 publications

(23 citation statements)

References 36 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, recent computational studies have identified the histamine H 2 receptor antagonist famotidine as an inhibitor of 3CL pro [5] and of PL pro [36,37] (Fig. 1), thus implying a direct antiviral effect on SARS-CoV-2.…”

Section: Histamine and Covid-19 Bioinformatics/ Drug Repurposing Studiesmentioning

confidence: 99%

Histamine receptors and COVID-19

Ennis

Tiligada

2020

Inflamm. Res.

View full text Add to dashboard Cite

Objective Reports that the over-the-counter histamine H 2 receptor antagonist famotidine could help treat the novel coronavirus disease (COVID-19) appeared from April 2020. We, therefore, examined reports on interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and histamine receptor antagonists. Methods A systematic literature search was performed by 19 September 2020, and updated on 28 October 2020, in PubMed, Scopus, Cochrane Library and Google Scholar using (COVID-19 OR coronavirus OR SARS-CoV-2) AND (histamine antagonist OR famotidine OR cimetidine). ClinicalTrials.gov was searched for COVID-19 and (famotidine or histamine). Results Famotidine may be a useful addition in COVID-19 treatment, but the results from prospective randomized trials are as yet awaited. Bioinformatics/drug repurposing studies indicated that, among several medicines, H 1 and H 2 receptor antagonists may interact with key viral enzymes. However, in vitro studies have to date failed to show a direct inhibition of famotidine on SARS-CoV-2 replication. Conclusions Clinical research into the potential benefits of H 2 receptor antagonists in managing COVID-19 inflammation began from a simple observation and now is being tested in multi-centre clinical trials. The positive effects of famotidine may be due to H 2 receptor-mediated immunomodulatory actions on mast cell histamine–cytokine cross-talk, rather than a direct action on SARS-CoV-2.

show abstract

Section: Histamine and Covid-19 Bioinformatics/ Drug Repurposing Studiesmentioning

confidence: 99%

Histamine receptors and COVID-19

Ennis

Tiligada

2020

Inflamm. Res.

View full text Add to dashboard Cite

show abstract

“…Previous studies have suggested that famotidine may have unintended anti-viral properties due to binding of famotidine to the SARS-CoV-2 chymotrypsin-like protease and papain-like protease, enzymes necessary for replication and survival of the virus, respectively. 14 , 15 , 16 Pharmacokinetic analysis of famotidine previously showed poor absorption and low volume of distribution, suggesting that IV administration would be advantageous, if not necessary, to achieve sufficient plasma levels of famotidine for the treatment of COVID-19. 15 It is also possible that famotidine has no prophylactic effect but does have a role in limiting illness after symptom onset or preventing severe complications.…”

Section: Discussionmentioning

confidence: 99%

Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study

et al. 2023

View full text Add to dashboard Cite

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus-19 disease pandemic. The H-2 blocker famotidine has been suggested as an FDAapproved drug that could potentially be repurposed for treatment of COVID-19. Famotidine has since been shown to improve patient outcomes and reduce symptom severity in patients acutely ill with COVID-19. Other studies have suggested that proton pump inhibitors (PPIs) might have an association with COVID-19. Objective. The purpose of the present study was to determine whether famotidine or any other antireflux medications have a prophylactic or detrimental effect for SARS-CoV-2 infection when taken regularly for the management of acid reflux.Methods. An anonymous, web-based survey was distributed via email to adult otolaryngology patients to collect demographic data, past medical history, medication history, incidence of symptoms associated with COVID-19, potential exposure to SARS-CoV-2, and results of any PCR or serological testing. Associations between reflux medications and incidence of COVID-19 cases were analyzed. Statistical analysis was performed using SPSS. Chisquare with Fisher's exact test, Point-Biserial correlation, Kendall's-tau-b, independent samples t test, and the Mann-Whitney U test were used as appropriate. A binary logistic regression model was fit to determine probability of COVID-19 cases after adjustment for other risk factors. Results. There were 307 patients who responded to the survey. The average age of respondents was 52.63 § 17.03. Famotidine use was not associated with incidence of laboratory-confirmed (P= 0.717) or symptomatically suspected (P= 0.876) COVID-19. No other reflux medications were found to be significant predictors for laboratory-confirmed or suspected COVID-19 (P> 0.05). Younger age (odds ratio [OR] = 1.043, 95% CI: 1.020−1.065, P< 0.001), high risk obesity (OR = 4.005, 95% CI: 1.449−11.069, P= 0.007), and use of a corticosteroid nasal spray (OR = 3.529, 95% CI: 1.352−9.211, P= 0.010) were significant predictors for symptomatically suspected COVID-19 cases. Conclusions. There was no association between incidence of COVID-19 and use of reflux medications, including famotidine at doses used orally to manage reflux and high dose PPIs. Reflux medications did not protect against or increase the risk of COVID-19.

show abstract

“…Both of these proteases are critical for viral replication, and PLpro additionally has effects on ubiquitination and interferon that may dysregulate host innate immunity. In silico methods, including virtual ligand screening of SARS-CoV-2 proteins against libraries of compounds, predict the binding of famotidine to Mpro (23), PLpro (24,25), or both (26). These in silico predictions await laboratory target validation.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19

Alper

2020

Front. Med.

View full text Add to dashboard Cite

Famotidine is of interest as a possible treatment for COVID-19, with effects on disease-related symptoms and survival reported in observational and retrospective studies, as well as in silico predictions of binding to potential SARS-CoV-2 drug targets. Published studies of famotidine for COVID-19 have focused on acute illness, and none have reported on neuropsychiatric symptoms. This case study reports on an 18-year-old man who sought psychiatric treatment for depression and anxiety, disruptive interpersonal conflicts, and impairments in attention and motivation following mildly symptomatic illness with COVID-19. The neuropsychiatric symptoms, which had been present for 16 weeks at the time of the initial evaluation represented a significant departure from the patient's previous behavioral baseline. The patient had no prior psychiatric history preceding his illness with COVID-19, and no history of any prior treatment with psychopharmacological medications. Famotidine 20 mg twice daily administered orally was begun without any additional medications. At 1-week follow-up the patient was much improved. Improvement was sustained through 12 weeks of follow-up during which the patient continued to take famotidine without apparent side effects. With progression of the COVID-19 pandemic it has become evident that persistent disease-related symptoms may follow acute COVID-19 and may include neuropsychiatric symptoms. Controlled clinical research on famotidine for COVID-19 should follow, as well as the development of valid and reliable research diagnostic criteria to define and operationalize the features of a putative COVID-19 neuropsychiatric residual.

show abstract

Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2

Cited by 27 publications

References 36 publications

Histamine receptors and COVID-19

Histamine receptors and COVID-19

Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study

Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19

Contact Info

Product

Resources

About